Key Highlights
- 8.25% is the indicated pre-market gain for PepGen Inc. (NASDAQ:PEPG) on November 18, 2026, lifting the price to USD 4.20 from a calculated prior close of USD 3.88, a calculated move of USD 0.32.
- 25 million shares at USD 5.00 each were priced in the public offering announced on November 11, 2026, for expected gross proceeds of USD 125 million, with a 30-day option for up to 3,750,000 additional shares.
- 104.8 million USD in cash and marketable securities was reported at September 30, 2026, split between USD 22.0 million in cash and USD 82.8 million in securities, with a runway guided into 2028.
- 46.5% mean splicing correction was reported at week 13 for the 10 mg/kg cohort in the Phase 2 FREEDOM2 trial of PGN-EDODM1, versus 6.8% for pooled placebo, in myotonic dystrophy type 1.
What Moved PepGen Inc. (NASDAQ:PEPG) in Pre-Market Trading on November 18, 2026 (+USD 0.32, +8.25%)
The indicated pre-market price for PepGen Inc. (NASDAQ:PEPG) is USD 4.20 on November 18, 2026, a pre-market move of +8.25%. The calculated prior close, the November 17, 2026 regular-session close, is USD 3.88 (USD 4.20 divided by 1.0825), and the calculated USD move is +USD 0.32. The indicated price is a calculated 16.0% below the USD 5.00 offering price set on November 11, 2026. A corroborated market Capitalization and pre-market Volume were not found.
The Rationale: Rebound After the USD 125 Million Offering for PepGen Inc. (NASDAQ:PEPG)
No new same-day announcement was identified in published coverage for November 18, 2026, so the move appears to be follow-through from the recent financing and trial update. As general context, shares often trade below a deal price after a large offering. On November 11, 2026 the company priced 25 million shares at USD 5.00 for expected gross proceeds of USD 125 million, with closing expected on or about November 13, 2026. On November 10, 2026 the company reported third quarter results, with the 12.5 mg/kg cohort fully enrolled and topline results expected in the first half of 2027. President and Chief Executive Officer James McArthur pointed to more than 135 doses administered in the open-label extension study.
Valuation, Liquidity and Risks for PepGen Inc. (NASDAQ:PEPG)
Cash and marketable securities of USD 104.8 million at September 30, 2026, plus USD 125 million of expected gross proceeds, imply a calculated combined total near USD 229.8 million before expenses. Third quarter Research and Development expense was USD 14.5 million, up 8% from USD 13.4 million, and general and administrative expense was USD 5.9 million, up 13% from USD 5.2 million. The nine month net loss narrowed to about USD 55.0 million from USD 71.3 million. Risks are specific. A partial U.S. clinical hold placed in March 2026 remains in effect, renal biomarker elevations are under safety monitoring, and the lead program has no revenue.
Where Things Stand
PepGen Inc. (NASDAQ:PEPG) is indicated up 8.25% in pre-market trading on November 18, 2026, at USD 4.20, a calculated gain of USD 0.32 from a prior close of USD 3.88. No new same-day catalyst was identified in published coverage. The backdrop is a USD 125 million public offering priced at USD 5.00 on November 11, 2026, third quarter results with USD 104.8 million in cash and securities, and Phase 2 data showing 46.5% splicing correction at 10 mg/kg. A partial clinical hold, dilution and the lack of Revenue remain key risks, and pre-market moves can reverse at the 9:30 a.m. ET open. This is not Investment advice.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...